1. Home
  2. MURA vs AREN Comparison

MURA vs AREN Comparison

Compare MURA & AREN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MURA
  • AREN
  • Stock Information
  • Founded
  • MURA 2013
  • AREN 2016
  • Country
  • MURA Ireland
  • AREN United States
  • Employees
  • MURA N/A
  • AREN N/A
  • Industry
  • MURA
  • AREN Medical/Dental Instruments
  • Sector
  • MURA
  • AREN Health Care
  • Exchange
  • MURA Nasdaq
  • AREN Nasdaq
  • Market Cap
  • MURA 57.2M
  • AREN 59.8M
  • IPO Year
  • MURA N/A
  • AREN N/A
  • Fundamental
  • Price
  • MURA $4.00
  • AREN $1.40
  • Analyst Decision
  • MURA Strong Buy
  • AREN
  • Analyst Count
  • MURA 4
  • AREN 0
  • Target Price
  • MURA $16.00
  • AREN N/A
  • AVG Volume (30 Days)
  • MURA 239.2K
  • AREN 81.8K
  • Earning Date
  • MURA 11-13-2024
  • AREN 11-14-2024
  • Dividend Yield
  • MURA N/A
  • AREN N/A
  • EPS Growth
  • MURA N/A
  • AREN N/A
  • EPS
  • MURA N/A
  • AREN N/A
  • Revenue
  • MURA N/A
  • AREN $234,396,000.00
  • Revenue This Year
  • MURA N/A
  • AREN $12.73
  • Revenue Next Year
  • MURA N/A
  • AREN $71.95
  • P/E Ratio
  • MURA N/A
  • AREN N/A
  • Revenue Growth
  • MURA N/A
  • AREN 45.45
  • 52 Week Low
  • MURA $2.87
  • AREN $0.56
  • 52 Week High
  • MURA $5.62
  • AREN $2.35
  • Technical
  • Relative Strength Index (RSI)
  • MURA 66.06
  • AREN 52.85
  • Support Level
  • MURA $3.55
  • AREN $1.17
  • Resistance Level
  • MURA $4.05
  • AREN $1.32
  • Average True Range (ATR)
  • MURA 0.24
  • AREN 0.15
  • MACD
  • MURA 0.07
  • AREN -0.01
  • Stochastic Oscillator
  • MURA 91.35
  • AREN 56.45

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

About AREN The Arena Group Holdings Inc.

The Arena Group Holdings Inc is a tech-powered media company that fuses technology, iconic brands, and marketing to deliver vibrant content and experiences that reach million users each month. The company creates robust digital destinations that delight consumers with powerful journalism, news about the things such as favorite sports teams, advice on investing, the inside scoop on personal finance, and the latest on lifestyle essentials. The Company operates in one reportable segment which focuses on a publishing platform. The company generates revenue from Digital and Print, where the majority is generated from Digital. The company owns and operates TheStreet, The Spun, Parade, and Men's Journal and powers more than 320 independent Publisher Partners.

Share on Social Networks: